Product Description
Azeliragon is an oral, small-molecule inhibitor of RAGE, a cell-surface receptor of the immunoglobulin superfamily. (Sourced from: https://www.alzforum.org/therapeutics/azeliragon)
Mechanisms of Action: RAGE Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Breast CancerOrphan Drug - GlioblastomaOrphan Drug - Pancreatic Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: vTv
Company Location: HIGH POINT NC 27265
Company CEO: Paul J. Sekhri
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Spain, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
- Clinical Outcomes Reported - vTv presented P1 Pancreatic Cancer results on 2024-05-31 for Azeliragon
- Clinical Outcomes Reported - vTv presented P2 Glioblastoma results on 2024-03-27 for Azeliragon
Highest Development Phases
Phase 2: Glioblastoma|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 24-x347 | P1 |
Not yet recruiting |
Glioblastoma |
2027-10-31 |
23% |
2025-02-19 |
Primary Endpoints|Treatments |
| CAN-201 MPC | P2 |
Recruiting |
Pancreatic Cancer |
2025-02-01 |
50% |
2024-07-23 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| 2022-002801-36 | P2 |
Active, not recruiting |
Glioblastoma |
2026-03-01 |
24% |
||
| CAN 201 | P2 |
Active, not recruiting |
Glioblastoma |
2024-12-01 |
24% |
2024-11-13 |
Primary Endpoints|Treatments|Trial Status |
| CAN-401 | P2 |
Active, not recruiting |
Glioblastoma |
2024-09-30 |
55% |
2024-09-06 |
Primary Endpoints|Treatments|Trial Status |